209 related articles for article (PubMed ID: 36420890)
21. Hydroxychloroquine in lupus pregnancy.
Clowse ME; Magder L; Witter F; Petri M
Arthritis Rheum; 2006 Nov; 54(11):3640-7. PubMed ID: 17075810
[TBL] [Abstract][Full Text] [Related]
22. Acute generalized exanthematous pustulosis with a focus on hydroxychloroquine: A 10-year experience in a skin hospital.
Nili A; Zarei E; Ghamari A; Farid AS; Tavakolpour S; Daneshpazhooh M; Mahmoudi H
Int Immunopharmacol; 2020 Dec; 89(Pt B):107093. PubMed ID: 33091817
[TBL] [Abstract][Full Text] [Related]
23. The necessity of patch testing in determining the causative drug of AGEP.
Mofarrah R; Mofarrah R; Oshriehye M; Ghobadi Aski S; Nazemi N; Nooshiravanpoor P
J Cosmet Dermatol; 2021 Jul; 20(7):2156-2159. PubMed ID: 33190407
[TBL] [Abstract][Full Text] [Related]
24. Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy.
Abarientos C; Sperber K; Shapiro DL; Aronow WS; Chao CP; Ash JY
Expert Opin Drug Saf; 2011 Sep; 10(5):705-14. PubMed ID: 21417950
[TBL] [Abstract][Full Text] [Related]
25. Low incidence of intrauterine growth restriction in pregnant patients with systemic lupus erythematosus taking hydroxychloroquine.
Canti V; Scarrone M; De Lorenzo R; Ramirez GA; Erra R; Bordoli S; Cella S; Schmit E; Rosa S; Castiglioni MT; Rovere-Querini P
Immunol Med; 2021 Sep; 44(3):204-210. PubMed ID: 33417532
[TBL] [Abstract][Full Text] [Related]
26. Prolonged acute generalized exanthematous pustulosis and atypical target-like lesions induced by hydroxychloroquine.
Otake-Irie H; Nakajima S; Okamoto N; Toichi E; Nomura T; Kabashima K
J Dermatol; 2020 Nov; 47(11):e387-e388. PubMed ID: 32770860
[No Abstract] [Full Text] [Related]
27. Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report.
Ameen Ismail A; Sadek SH; Hatata RM
BMC Ophthalmol; 2022 Nov; 22(1):434. PubMed ID: 36376841
[TBL] [Abstract][Full Text] [Related]
28. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.
Jallouli M; Francès C; Piette JC; Huong du LT; Moguelet P; Factor C; Zahr N; Miyara M; Saadoun D; Mathian A; Haroche J; De Gennes C; Leroux G; Chapelon C; Wechsler B; Cacoub P; Amoura Z; Costedoat-Chalumeau N;
JAMA Dermatol; 2013 Aug; 149(8):935-40. PubMed ID: 23824340
[TBL] [Abstract][Full Text] [Related]
29. Systemic lupus erythematosus and hydroxychloroquine-related acute intermittent porphyria.
Esteve-Valverde E; Tapiz-Reula A; Ruiz D; Alijotas-Reig J
Rheumatol Int; 2020 May; 40(5):777-783. PubMed ID: 31865445
[TBL] [Abstract][Full Text] [Related]
30. Clindamycin-induced acute generalized exanthematous pustulosis: A case report.
Aiempanakit K; Apinantriyo B
Medicine (Baltimore); 2020 May; 99(21):e20389. PubMed ID: 32481338
[TBL] [Abstract][Full Text] [Related]
31. Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: a pilot study.
Cairoli E; Danese N; Teliz M; Bruzzone MJ; Ferreira J; Rebella M; Cayota A
Lupus; 2015 Oct; 24(11):1204-9. PubMed ID: 25852050
[TBL] [Abstract][Full Text] [Related]
32. Cyclosporine for corticosteroid-refractory acute generalized exanthematous pustulosis due to hydroxychloroquine.
Castner NB; Harris JC; Motaparthi K
Dermatol Ther; 2018 Sep; 31(5):e12660. PubMed ID: 30152569
[TBL] [Abstract][Full Text] [Related]
33. Clinical features of acute generalized exanthematous pustulosis caused by hydroxychloroquine in rheumatology patients and exploration of
Luo F; Yuan XM; Xiong H; Yang YZ; Chen CM; Ma WK; Yao XM
Front Med (Lausanne); 2023; 10():1161837. PubMed ID: 37089611
[TBL] [Abstract][Full Text] [Related]
34. [Pleading to maintain hydroxychloroquine throughout Lupus pregnancies].
Costedoat-Chalumeau N; Amoura Z; Le Thi Huong D; Wechsler B; Piette JC
Rev Med Interne; 2005 Jun; 26(6):467-9. PubMed ID: 15936475
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose.
Wakiya R; Kameda T; Nakashima S; Shimada H; Fahmy Mansour MM; Kato M; Miyagi T; Kadowaki N; Dobashi H
Intern Med; 2020 Sep; 59(17):2105-2112. PubMed ID: 32522920
[TBL] [Abstract][Full Text] [Related]
36. Successful treatment with hydroxychloroquine for systemic lupus erythematosus with cutaneous involvement accompanied by a xanthomatous reaction.
Takezawa K; Ueda-Hayakawa I; Yamazaki F; Kambe N; Son Y; Okamoto H
Lupus; 2020 Jan; 29(1):79-82. PubMed ID: 31789124
[TBL] [Abstract][Full Text] [Related]
37. Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus.
Fasano S; Messiniti V; Iudici M; Coscia MA; Ciccia F
Lupus Sci Med; 2023 Jan; 10(1):. PubMed ID: 36631164
[TBL] [Abstract][Full Text] [Related]
38. Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data.
Clowse MEB; Eudy AM; Balevic S; Sanders-Schmidler G; Kosinski A; Fischer-Betz R; Gladman DD; Molad Y; Nalli C; Mokbel A; Tincani A; Urowitz M; Bay C; van Noord M; Petri M
Lupus Sci Med; 2022 Mar; 9(1):. PubMed ID: 35318256
[TBL] [Abstract][Full Text] [Related]
39. Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine.
Haraszti S; Sendil S; Jensen N
Am J Case Rep; 2020 Oct; 21():e926901. PubMed ID: 33097683
[TBL] [Abstract][Full Text] [Related]
40. Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy.
; Silver R; Craigo S; Porter F; Osmundson SS; Kuller JA; Norton ME
Am J Obstet Gynecol; 2023 Mar; 228(3):B41-B60. PubMed ID: 36084704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
